echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca's first-half results are in tatout! Revenue, profit and cash flow all continued to grow.

    AstraZeneca's first-half results are in tatout! Revenue, profit and cash flow all continued to grow.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Read: On July 30, AstraZeneca released its second-quarter 2020 results.
    July 30, AstraZeneca reported second-quarter 2020 results: total revenue of $6.275 billion, up 8% yoY, product sales of $6,048 million, up 6% year-on-year, and core earnings per share (EPS) at $0.96, up 32% year-on-year.
    's first-half revenue was $12.629 billion, up 12% YoY, product sales were $12.359 billion, up 11% YoY, and core EPS was $2.01, up 24% YoY.
    AstraZeneca's performance remained strong against the backdrop of the GLOBAL PANDEMIC of COVID-19, with revenue, profits and cash flow continuing to grow.
    the first half of the year, innovation drugs, the three core areas, each market continued to grow: - Innovative drugs increased significantly: revenues of $6.353 billion, up 42%, of which $1.406 billion in emerging markets, up 71%, these drugs accounted for 50% of global revenue (40% in 2019).
    - Three Core Therapeutics Areas: (1) Oncology Revenue of $5.324 billion, up 28%.
    (2) Cardiovascular, Kidney and Metabolic Business (CVRM) revenue was $2.265 billion, up 8%.
    (3) Revenue from the respiratory and immunology business was $2.676 billion, up 5 percent, with total revenue from the respiratory and immunology business falling 11 percent to $1.122 billion in the second quarter, reflecting the negative impact of COVID-19 on Pulmicort in the Chinese market.
    - Growth continued in every market: (1) Emerging market revenues rose 9 per cent to $4.329 bn, with Revenues in China up 10 per cent to $2.659bn, up 7 per cent on second-quarter revenues of $1.243bn.
    (2) U.S. market revenue rose 13 percent to $4.177 billion.
    (3) European market revenue sharply increased 17% to $2,447 million.
    the first half of the year, the cancer target drug Tagrisso ($2,016 million, up 43 percent), the anti-PD-L1 therapy Imfinzi ($954 million, up 51 percent), and the PARP inhibitor Lynparza ($816 million, up 57 percent), and the new drug Calence ($195 million), which was sold in the oncology business, exceeded expectations.
    SGLT2 inhibitors Farxiga ($848 million, up 17 percent) and anticoagulant Brilinta ($845 million, up 15 percent), Symbicort ($1.442 billion, up 23 percent) and Fasenra ($426 million, up 44 percent) in CVRM's business.
    in pipeline, the company has made further significant progress, highlighted by the overwhelming success of Tagrisso in the treatment of early EGFR mutation sucellular lung cancer Phase III ADAURA trials, and Farxiga's expansion of its therapeutic potential beyond diabetes. in addition,
    , the company has strengthened its oncology partnership with First Three, reaching a $6 billion partnership on the new product DS-1062. in addition,
    the company is rapidly responding to the outbreak and is now able to deliver more than 2 billion doses of the vaccine product AZD122, while accelerating the development of monoclonal antibody therapy and accelerating new clinical trials in patients affected by COVID-19.
    the company's 2020 financial guidance remains unchanged and total revenue is expected to grow by double-digit percentages in the high single digits to the lowest.
    Core EPS is expected to grow by a median-to-to-to-high double-digit percentage.
    the risks and uncertainties associated with the impact of the outbreak, the company expects the quarterly results to continue to change.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.